Ecor1 Capital's book
15 companies · priced by our data| Company | Industry | Valuation | $/share | First invested | Role |
|---|---|---|---|---|---|
| Freenome | Decision/Risk Analysis | $2.2B | — | — | |
| Eikon Therapeutics (NAS: EIKN) | — | $971.7M | — | — | |
| ReCode Therapeutics | — | $700.0M | — | — | |
| Cellares | — | $675.0M | — | — | |
| Dewpoint Therapeutics | — | $500.0M | — | — | |
| Diagonal Therapeutics | Drug Discovery | $458.5M | — | — | |
| Attovia Therapeutics | — | $370.0M | — | — | |
| Ashvattha Therapeutics | — | $310.0M | — | — | |
| Ajax Therapeutics | Drug Discovery | $192.5M | — | — | |
| Omniox | — | $150.0M | — | — | |
| + 5 more companies · a free account shows the top 25 | |||||
Free account
See the whole book
- ·The book's top 25 — of 15 recorded positions
- ·Watchlist + alerts for Ecor1 Capital's activity
Create free account
No card required